George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
PL I beg to differ, best test in the world binding to N and P at a time when the focus will rightly be on Sensitivity to provide a Green Light for attendance at meetings and the like going forward and dare I say it flights and such as well. As we all know Covid has not gone away and folk will tire of catching it over and over again not to mention the risk of a seriously nasty varient. I think time will prove Avacta are right to complete this second generation LFT. The truth about the rubbish tests is out there dont think that will happen again, although has anyone seen Sensitivity numbers of the Vatic Test at ct anything?
Once established as the best in world Covid LFT it becomes a no effort income stream for Avacta so whats not to like, expect perhaps ongoing testing to confirm sensitivity with variants. Anyhoo other AffiDX tests are hopefully not that far off.
As I said months ago AS did not strike me as someone likely to give up and admit defeat on his flagship IVD product. There will be more difficulties I expect with driving down costs and improving its Green Credentials than other aspects. But we will see Shortly.
Expensive and immediately redundant when AVA6000 is proven. Am looking forward to tomorrorow with some concerns given AS propensity for crashing the share price deliberately or otherwise, on the last occasion he must have surely been aware of consequences of what he said so I count ghat as deliberate. Anyhoo, fingers crossed and GLA, dont forget early to bed cos you will be up early tomorrow.
Regarding dosage, from what I have read and understood large dosage may not necessarily deliver the best outcome for patients, rather more cycles may be the dosing regime selected as giving best results. Both approaches equally valid and only possible because of reduced toxicity. This will I gather be the focus of attention under phase 1b.
In my opinion no one could have anticipated the shenanigans that the present Government and its acolytes got up to in relation to Covid testing. The was a real effort to ensure PCR testing delivered billions to a select few, look at the delays and downright obstruction BAMS was subject to and I could go on but am frankly bored by it. We are where we are and hopefully AS can realise significant profit from the Diagnostics Division as a whole, or otherwise sell it off, and make a success of AVA6000 and the preCISION pipeline. All will be revealed in a little while. Millionaires made of those with holdings of 100k and more. Time will tell GLA LTH we must truely have the patience of Saints to get this far and still be holding but hey ho, nothing ventured nothing gained.
GMCC, I agree there is a lot to play for in the diagnostics space. Lets hope we hear that there are new products nearing approval, less than two would strike me as dilatory given the resources available, we shall soon see.
Regarding the Avacta LFT we have no idea what the full scope of work on the LFT is, it may be its beyond antibody replacement. I hope this is indeed the case and we see an improved product with greener credentials. Again, since we have been told b all we are left guessing. But hey ho all to be revealed Shortly.
Regarding Herd Immunity, there is no such thing in relation to Covid if we are to believe what the scientists have advised previously. Catch it and catch it again, combined with ones brain apparently shrinking a little with each infection absolutely b****y marvellous!
Not sure director buying would be possible given the AVA6000 information they are undoubtedly aware of. But hey ho, another week slides by without adverse comment and another top tier appointment. The only way way is up and my guess is that will happen Shortly (i.e. anytime between now and Christmas ;-)
Dear me, call me stupid but I actually respect and value both Ophidian and McNulty. I read what they say which is generally high value. I dont believe either would seek to deliverately mislead folk. Dosent mean I think that they have any obligation to do anything but it is a rare breed of bas***d who seeks to deliberately mislead and in my opinion Ophidian and McNulty are not that, in fact quite the reverse. Dosent mean I act on their opinions though, my cash my responsibility. I do think we have that rare breed on this board but not the aforementioned I think.
Seems likely to me that a numbef of LFTs will fail Sensitivity Checks so Abacta is actually likely to be well positioned with its second generation offering assuming they do resolve the cost of goods issue. Onward and upward.